A Randomized, Controlled, Open-Label Study of the Long-Term Impact on Functioning Using Atomoxetine Hydrochloride Compared to Other Early Standard Care in the Treatment of Attention-Deficit/Hyperactivity Disorder in Treatment-Naive Children and Adolescents

Trial Profile

A Randomized, Controlled, Open-Label Study of the Long-Term Impact on Functioning Using Atomoxetine Hydrochloride Compared to Other Early Standard Care in the Treatment of Attention-Deficit/Hyperactivity Disorder in Treatment-Naive Children and Adolescents

Completed
Phase of Trial: Phase III

Latest Information Update: 05 Sep 2014

At a glance

  • Drugs Atomoxetine (Primary) ; Methylphenidate; Reboxetine
  • Indications Attention-deficit hyperactivity disorder
  • Focus Therapeutic Use
  • Acronyms ADHD-LIFE
  • Sponsors Eli Lilly
  • Most Recent Events

    • 29 Jun 2012 Additional trial location added as reported by European Clinical Trials Database.
    • 01 Sep 2010 Results of an analysis of the secondary endpoint analysis of the WFRIS score presented at the 23rd Annual Congress of the European College of Neuropsychopharmacology
    • 01 Sep 2010 Other early standard therapy identified as methylphenidate or reboxetine, and descriptors added
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top